Eric Langer | 10/23/2014
Biopharmaceutical companies that get stuck with legacy technologies, including older stainless steel equipment, and older processes, end up watching as competitors transition to more efficient, cost-effective platforms. But this isn’t just a cost-of-production issue; it goes to more strategic factors like being able to even participate in the emerging biosimilars markets, as well as being able to participate in global emerging economies.
Our 11thAnnual Report of Biopharmace...
To continue reading this story Click Here
RECOMMENDED
The Trust Equation: Why Transparency Defines the Future Winners in Contract Manufacturing
2025-12-17
Upcoming Events
SmartLab Exchange USA
April 20-21, 2026
The Logan, Philadelphia, USA
Register Now |
View Agenda |
Learn More